Halozyme Therapeutics, Inc. (HALO) · Sep 16, 2026 · New debt

Halozyme plans $1.05B convertible offering as buybacks and acquisitions compete for cash

$1.05B convertible offering — $1.05B due 2033; proceeds partly repurchase 0.25% 2027 and 1.00% 2028 notes

Halozyme is raising up to $1.2B through convertibles, partly refinancing near-term notes while preserving room for acquisitions and strategic investment.

Halozyme enters this financing as a fast-growing, royalty-led drug-delivery platform: ENHANZE royalties are scaling through partner products, while Hypercon and Surf Bio broaden the pipeline of technologies it can license. Its latest reported quarter showed $481 million of revenue, $308 million of royalty revenue, and raised 2026 guidance to $1.835–$1.910 billion of revenue and $8.65–$9.00 of non-GAAP diluted EPS. This is a capital-structure move, not a change to the operating story. Halozyme proposes $1.05 billion of convertible notes due 2033, with a possible $150 million upsize. The conversion price, coupon and other key economics are still to be negotiated, so the filing does not yet establish the eventual dilution or interest burden. The immediate use is partly refinancing and maturity management. Proceeds are expected to fund capped calls and cash repurchases of selected 2027 and 2028 convertible notes, extending the liability profile while the capped calls are designed to reduce potential dilution. The strategic upside is flexibility, but the trade-off is real. Remaining proceeds may support working capital, capital spending, acquisitions, strategic transactions or later note repurchases. 〔0〕 That gives a cash-generative business more room to pursue Hypercon, Surf Bio or other expansion without spending all operating cash immediately, but it also adds a new senior obligation and potentially shifts capital away from the $1 billion share-repurchase program announced earlier in 2026. The latest quarterly release reported $231.9 million of cash, restricted cash and marketable securities at June 30, 2026, alongside the raised outlook and continued partner expansion. | Item | Filing detail |

Proposed notes$1.05 billion aggregate principal; due October 1, 2033 (Press Release)
Upsize optionUp to an additional $150 million (Press Release)
Existing notes targeted0.25% notes due 2027 and 1.00% notes due 2028 (Press Release)
Dilution protectionPrivately negotiated capped calls intended to reduce potential dilution (Press Release)
Other usesWorking capital, capital expenditures, potential acquisitions and strategic transactions (Press Release)

Bottom line: Halozyme is using its strong operating position to extend maturities and preserve strategic firepower, but it is doing so with a larger debt obligation and unresolved conversion economics. The event matters for capital allocation more than for the underlying ENHANZE growth story.

What to watch next

Pricing and note-repurchase terms

Original filing on SEC EDGAR

More Halozyme Therapeutics, Inc. news

Halozyme plans $1.05B convertible offering as buybacks and acquisitions compete for cash | HALO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.